Efficacy and safety of intramuscular administration of allogeneic adipose tissue derived and expanded mesenchymal stromal cells in diabetic patients with critical limb ischemia with no possibility of revascularization: study protocol for a randomized controlled double-blind phase II clinical trial (The NOMA Trial)혈관재생 가능성이 없는 위독한 사지 허혈이 있는 당뇨병 환자에서 동종 지방 조직 유래 및 확장 중간엽 기질 세포의 근육내 투여의 효능 및 안전성: 무작위 대조 이중 맹검 2상 임상 시험을 위한 연구 프로토콜(The NOMA Trial)Study Protocol Published on 2021-09-062022-09-10 Journal: Trials [Category] SARS, 비임상, 임상, [키워드] adipose Adipose tissue Adipose-derived mesenchymal stromal cells Administered administration Advanced therapy medicinal products adverse event adverse events Allogeneic Angiogenesis animal model animal models antiplatelet assigned breath Cell Cell therapy chronic clinical development Clinical practice clinical trial control group Critical Critical limb ischemia current data set demonstrated develop diabetes Diabetes Mellitus diabetic patient dose double-blind Efficacy eligible patient evaluate evaluated feasibility Health Organization health problem humans IMPROVE induce intramuscular Ischemia life limb lower limb Mesenchymal stromal cells multicenter outcome parameters Patient Phase II clinical trial placebo-controlled trial Primary outcome protocol public health Quality of life Randomized Randomly Registration Research revascularization secondary Secondary outcomes shown statins step stromal cell stromal cells study period Study protocol Tertiary the disease therapeutic therapeutic option therapeutic options therapy tissue tissue perfusion Treatment treatment group Trial registration type 2 diabete Type 2 diabetes mellitus World Health Organization [DOI] 10.1186/s13063-021-05430-2 PMC 바로가기 [Article Type] Study Protocol
Animal experiments show impact of vaccination on reduction of SARS-CoV-2 virus circulation: A model for vaccine development?SARS-CoV-2 바이러스 순환 감소에 대한 백신 접종의 영향을 보여주는 동물 실험: 백신 개발 모델?Review Published on 2021-09-012022-09-12 Journal: Biologicals : journal of the International Associa [Category] SARS, 진단, [키워드] animal Animal experiment animal model animal models Blood bronchoalveolar clinical development clinical trials COVID-19 disease Efficacy eight experiments exposure Exposure experiments Intention Lungs nasal swab neutralizing antibody predicted reduced reduction retrieved SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 virus shown Standardization tested Transmission trials vaccination Vaccine Vaccine development vaccine platform Viral load viral replication Viral RNA viral shedding virus excretion [DOI] 10.1016/j.biologicals.2021.08.001 PMC 바로가기 [Article Type] Review
Trans-ethnic genome-wide association study of severe COVID-19중증 COVID-19에 대한 인종 간 게놈 전체 연관성 연구Article Published on 2021-08-312022-09-10 Journal: Communications Biology [Category] MERS, 바이오마커, 변종, 유전자 메커니즘, 임상, 치료기술, [키워드] ABO adaptive adaptive immune system Adaptive immunity allele frequencies allele frequency Blood Group blood group system caused Chinese clinical development Clinical symptoms contributing to Control controls COVID-19 COVID-19 Host Genetics Initiative COVID-19 severity European followed by FOXP4 FOXP4-AS1 frameshift Genetic variant genome-wide association Genome-wide association studies Genome-wide association study genotyped highlight Hospitalized identify Immunity individuals Infection initiative insertion intronic variant loci MEF2B Meta-analysis Mild Odds ratio Patient rs8176719 sequenced Severe case severe COVID-19 severe disease Symptoms tested viral infection [DOI] 10.1038/s42003-021-02549-5 PMC 바로가기 [Article Type] Article
ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker강력하고 광범위한 코로나바이러스 차단제로서의 ACE2 표적 단클론항체Article Published on 2021-08-252022-09-10 Journal: Signal Transduction and Targeted Therapy [Category] Fulltext, SARS, 변종, 진단, 치료제, [키워드] ACE2 affecting Alanine angiotensin B.1.1.7 B.1.351 B.1.617.1 binding blocked CDR3 clinical development coronavirus Coronaviruses COVID-19 cryo cryo-EM D614G domain Drug development entry receptor epitope Evolution HCoV HCoV-NL63 heavy chain human ACE2 human Angiotensin-converting enzyme in vitro Infection Infectious diseases live SARS-CoV-2 management mice monoclonal antibody multiple coronaviruses mutant non-human primate non-human primates P.1 physiological activities physiological activity Prophylactic provided residue SARS-CoV SARS-CoV-2 SARS-COV-2 infection Toxicity variant virus [DOI] 10.1038/s41392-021-00740-y PMC 바로가기 [Article Type] Article
Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological PerspectiveReview Published on 2021-08-252022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] ADR ADRS Adverse Adverse drug reaction adverse event approval arising clinical development concerning coronavirus disease Course COVID-19 COVID-19 vaccines Cutaneous cytokine profile determine Efficacy Exanthema group immunogenic reaction Inflammatory injection site insight natural infection Numerous occur outcome Patient patients performed profiles reached reaction required Research SARS-CoV-2 Side effect Specific subset T-cell Th1 Th2 Tregs type I interferons Vaccine Vaccines [DOI] 10.3390/vaccines9090944 PMC 바로가기 [Article Type] Review
Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infectionSARS-COV-2 감염을 치료하기 위해 에스트로겐 수용체 조절제 Raloxifene을 재구성Review Published on 2021-08-172022-08-31 Journal: Cell Death and Differentiation [Category] SARS, 신약개발, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Anti-inflammatory antiviral properties attack rate candidate caused clinical development clinical trial clinical trials coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patients Drug development Efficacy endurance eradication Estrogen estrogen receptor identify immune memory Infection Infectious diseases pandemic Prophylactic raloxifene repurposing respiratory SARS-CoV-2 SARS-COV-2 infection selective therapeutic drug treat Treatment Vaccine Vaccines virus [DOI] 10.1038/s41418-021-00844-6 PMC 바로가기 [Article Type] Review
Editorial: Post-Exposure Prophylactic Neutralizing Monoclonal Antibodies to SARS-CoV-2 for Individuals at High Risk for COVID-19사설: COVID-19 고위험군 개인을 위한 SARS-CoV-2에 대한 노출 후 예방 중화 단일클론 항체Editorial Published on 2021-08-162022-09-11 Journal: Medical science monitor : international medical jo [Category] SARS, 변종, 진단, [키워드] accelerated acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 approval approvals approved authorization bamlanivimab Casirivimab children clinical development Clinical studies clinical study coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 progression diagnostic drug editorial Effectiveness Emergency Emergency use Emergency use authorization etesevimab EUA exposure to FDA food high risk Imdevimab individual initial Mild mild to moderate Moderate COVID-19 monoclonal antibody monotherapy Neutralizing neutralizing monoclonal antibodies neutralizing monoclonal antibody Older pandemic Preclinical Prevent progression Prophylactic REGEN-COV Regulatory Regulatory Authorities respiratory SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe COVID-19 therapeutic therapy treat US Food and Drug Administration Vaccine variants of SARS-CoV-2 [DOI] 10.12659/MSM.934393 PMC 바로가기 [Article Type] Editorial
A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents항 바이러스제를 평가하기 위해 공기 액체 계면에서 1 차 인간 상피 세포에서 강력한 SARS-COV-2 복제 모델Article Published on 2021-08-012022-09-10 Journal: Antiviral Research [Category] 신약개발, 치료제, [키워드] added Air-liquid interface airway epithelial cell Antiviral antiviral agent antivirals apical side approved AT-511 AT-527 basolateral side Cell clinical development clinical testing collected Culture culture medium D614G dose-dependent inhibition drug EIDD-1931 epithelial cells GS-441524 human epithelial cell IFN in vitro infectious virus titer infectious virus titers inhibit inhibitor medium molnupiravir nucleoside parent nucleoside primary cell Primary human airway epithelial cells Protein Remdesivir remdesivir) replicate robust SARS-CoV-2 SARS-CoV-2 infections SARS-CoV-2 isolates SARS-CoV-2 replication selected shown tracheal Treatment Viral viral replication Viral RNA virus virus titers were infected [DOI] 10.1016/j.antiviral.2021.105122 PMC 바로가기 [Article Type] Article
A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agentsArticle Published on 2021-08-012022-10-27 Journal: Antiviral Research [Category] COVID-19, [키워드] added Air-liquid interface airway epithelial cell Antiviral antiviral agent antivirals apical side approved AT-511 AT-527 basolateral side Cell clinical development clinical testing collected Culture D614G dose-dependent inhibition drug EIDD-1931 GS-441524 human epithelial cell IFN in vitro infectious virus titer inhibit inhibitor medium molnupiravir parent nucleoside Primary human airway epithelial cells Protein Remdesivir replicate robust SARS-CoV-2 SARS-CoV-2 infections SARS-CoV-2 isolates SARS-CoV-2 replication selected shown tracheal Treatment viral replication Viral RNA virus were infected [DOI] 10.1016/j.antiviral.2021.105122 PMC 바로가기 [Article Type] Article
A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agentsArticle Published on 2021-08-012022-10-27 Journal: Antiviral Research [Category] Coronavirus, COVID-19, SARS, [키워드] added Air-liquid interface airway epithelial cell Antiviral antiviral agent antivirals apical side approved AT-511 AT-527 basolateral side Cell clinical development clinical testing collected Culture D614G dose-dependent inhibition drug EIDD-1931 GS-441524 human epithelial cell IFN in vitro infectious virus titer inhibit inhibitor medium molnupiravir parent nucleoside Primary human airway epithelial cells Protein Remdesivir replicate robust SARS-CoV-2 SARS-CoV-2 infections SARS-CoV-2 isolates SARS-CoV-2 replication selected shown tracheal Treatment viral replication Viral RNA virus were infected [DOI] 10.1016/j.antiviral.2021.105122 PMC 바로가기 [Article Type] Article